Evidence map›Paper›PMID 41670105›Full record

ArticleRevista peruana de medicina experimental y salud publica2025

T-cell exhaustion and antibody response in SARS-CoV-2 vaccine recipients.

Iván Lozada-Requena, Camila A Arones-Santayana, Angela Vidal Riva, Joel de León, Arturo Pareja Cruz

Abstract read
In one paragraph

Article in Revista peruana de medicina experimental y salud publica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Iván Lozada-RequenaLaboratorio de Inmunología, Departamento de Ciencias Celulares y Moleculares, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Perú.ORCID http://orcid.org/0000-0002-3615-8964
Camila A Arones-SantayanaLaboratorio de Inmunología, Departamento de Ciencias Celulares y Moleculares, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Perú.ORCID http://orcid.org/0000-0002-6737-8521
Angela Vidal RivaCentro de Investigación de Virología, Universidad de San Martín de Porres, Lima, Perú.ORCID http://orcid.org/0009-0000-1729-666X
Joel de LeónCentro de Investigación de Virología, Universidad de San Martín de Porres, Lima, Perú.ORCID http://orcid.org/0000-0002-3664-8023
Arturo Pareja CruzCentro de Investigación de Virología, Universidad de San Martín de Porres, Lima, Perú.ORCID http://orcid.org/0000-0002-5988-5515

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OBJECTIVES.: To evaluate the percentage variations of the total lymphocyte population, T cells (TC), and their subpopulations; to characterize the cellular exhaustion profiles in CD4+ and CD8+ T cells; and to quantify anti-spike IgG antibody levels in individuals who received different vaccination schedules. MATERIALS AND METHODS.: We isolated PBMCs (peripheral blood mononuclear cells) from 45 vaccinated and 15 unvaccinated participants to measure TC percentages and MFI (mean fluorescence intensity) by flow cytometry. Additionally, we obtained serum from 42 vaccinated participants, 9 unvaccinated participants, and 20 pre-pandemic controls to measure the concentration of specific IgG antibodies against the SARS-CoV-2 spike protein, respectively. RESULTS.: Vaccination with 3P+1M+1P induced a lower %CD3+ than 3P+1M; a lower %CD8+ than 3P and 3P+1M, but a higher %CD4+ than 3P+1M. All groups, whether vaccinated or not, presented a negative correlation in which a higher %CD8+ corresponded to a lower %CD4+. Cellular exhaustion in CD4+PD1+ of the 3P+1M group was higher than in all CD8+PD1+ of all vaccination platforms including the unvaccinated, except for 3P and the vaccinated or unvaccinated platforms in CD4+PD1+. No significant differences were found in IgG (anti-spike) production across vaccination platforms. CONCLUSIONS.: Homologous or heterologous vaccination platforms from three doses onwards do not modify IgG (anti-spike) antibody production; however, they improve CD8+ T cell values, which constitute the most important subpopulation for the antiviral response against SARS-CoV-2.

Indexed as

Antibodies, ViralAntibody FormationCOVID-19COVID-19 VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusT-Cell ExhaustionAdultCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansImmunoglobulin GMaleMiddle AgedAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID41670105
PMCPMC12879979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.